Roche reported early Friday morning that neither of the Kadcyla-containing treatment arms in its Phase 3 study of the drug significantly improved PFS compared to Herceptin and chemotherapy. Kadcyla utilizes ImmunoGen's (IMGN) ADC technology.
ImmunoGen gapped open dramatically lower Friday morning, but has since moved in a narrow range. The stock is now down 5.09 at $5.76 on strong volume and has plummeted to a new low for the year.
For comments and feedback contact: editorial@rttnews.com
Business News